MedPath

The Effect of Continuous, Various Doses of Furosemide Drip on Hearing as Measured by Acoustic Emission

Conditions
Hearing Status
Registration Number
NCT00945386
Lead Sponsor
Rabin Medical Center
Brief Summary

Pediatric patients, during their illness often treated with furosemide (Lasix) continuous drip, often, with dosages above 4-6mg/kg/day (the recommended dose).

This study will monitor hearing status of these children prior to their therapy with furosemide, during this therapy and after.

Detailed Description

This study will record hearing status, by acoustic emission, of critically ill children, treated with different dosages of furosemide drip.

Acoustic emission test will be done prior to therapy and q48 hours during their course of treatment with furosemide drip.

Dosage of furosemide drip, boluses and other relevant medications (i.e - vancomycin, muscular relaxants, aminoglycosides etc) will be recorded.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • All children admitted to Pediatric ICU who are treated with furosemide continuous drip.
Exclusion Criteria
  • Children with known hearing abnormalities prior to treatment.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Pediatric ICU, Schneider Children's Hospital

🇮🇱

Petah Tikva, Israel

© Copyright 2025. All Rights Reserved by MedPath